Tag: heparin

1. For patients who underwent elective surgery and were at moderate to high risk of venous thromboembolism, pharmaco-thromboprophylaxis with low molecular weight heparin alone was noninferior to a combination of pharmaco-thromboprophylaxis and graduated compression stockings. Evidence Rating: 1 (Excellent) Venous thromboembolism (VTE) is associated with significant mortality and morbidity worldwide. For patients...
Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study 1. In three separate models, it was found that the combination of decreased health care access, food availability, and the economic impacts (both intentional and unintentional) of...
1. Anticoagulation at prophylactic dosing appeared to be associated with lower mortality and better prognosis in COVID-19 patients with coagulation dysfunction: i.e., sepsis-induced coagulopathy or a D-dimer greater than 6 times the upper limit or normal (30ug/mL). 2. No mortality benefit was found between heparin users and nonusers in other groups. Evidence...
1. Anticoagulation at prophylactic dosing appeared to be associated with lower mortality and better prognosis in COVID-19 patients with coagulation dysfunction: i.e., sepsis-induced coagulopathy or a D-dimer greater than 6 times the upper limit or normal (30ug/mL). 2. No mortality benefit was found between heparin users and nonusers other groups. Evidence...
Venous thromboembolism (VTE) is a common complication in patients with cancer. Often, VTEs are incidentally detected on imaging studies undertaken for cancer staging or evaluation of treatment response. Current guidelines recommend that the same anticoagulant treatment be used for both incidental pulmonary embolism (PE) and symptomatic PE in patients...
1. Patients undergoing percutaneous coronary intervention (PCI) mainly via radial approach receiving either bivalirudin or heparin, in addition to P2Y12 inhibitors, following myocardial infarction experienced similar rates of death from any cause, myocardial infarction, or major bleeding. 2. Patients who had ST-segment elevation myocardial infarction (STEMI) or non-STEMI myocardial infarctions...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Cost-Effectiveness of CT Screening in the National Lung Screening Trial The National Lung Screening Trial, a randomized controlled trial, demonstrated that lung cancer screening with low-dose computed tomography (CT) resulted in decreased...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Clinical Illness and Outcomes in Patients with Ebola in Sierra Leone With more than 10,100 reported cases, the current Ebola virus disease (EVD) outbreak is the largest and most widespread outbreak in...
1. Patients who were admitted to the general medicine service for a short stay had a very low risk of developing a blood clot in their veins (venous thromboembolism).  2. Furthermore, the risk of developing a blood clot was not necessarily affected by the receipt of pharmacologic prophylaxis against blood clots at...
Feb 6th - NEJM - Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding risk. Image: PD 1. Standard-duration rivaroxaban had no net clinical benefit over standard-duration enoxaparin for thromboprophylaxis in acutely ill hospitalized patients. 2. Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but...